Sugi Predict

Sugi Predict / Targets / BCL2L11

BCL2L11

Bcl-2-like protein 11 · O43521 · BCL2L11 on Sugi Atlas →

26,737 patent compounds predicted against BCL2L11, 23,157 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1329174 SCHEMBL1329174 0.56 3/20
SCHEMBL1329177 SCHEMBL1329177 0.56 3/20
SCHEMBL1540926 SCHEMBL1540926 0.82 2/20
SCHEMBL1540265 SCHEMBL1540265 0.69 2/20
SCHEMBL1540085 SCHEMBL1540085 0.68 2/20
SCHEMBL1540244 SCHEMBL1540244 0.65 2/20
SCHEMBL1540135 SCHEMBL1540135 0.65 2/20
SCHEMBL1540739 SCHEMBL1540739 0.64 2/20
SCHEMBL1540072 SCHEMBL1540072 0.57 2/20
SCHEMBL1540729 SCHEMBL1540729 0.56 2/20
SCHEMBL1540792 SCHEMBL1540792 0.56 2/20
SCHEMBL1540952 SCHEMBL1540952 0.55 2/20
SCHEMBL1541003 SCHEMBL1541003 0.53 2/20
Abt 737 Abt 737 (SCHEMBL158942) 1.00 1/20
Abt 737 Abt 737 (SCHEMBL170470) 1.00 1/20
Navitoclax Navitoclax (SCHEMBL522847) 1.00 1/20
SCHEMBL1540670 SCHEMBL1540670 0.93 1/20
SCHEMBL1540214 SCHEMBL1540214 0.92 1/20
SCHEMBL1540387 SCHEMBL1540387 0.92 1/20
SCHEMBL685145 SCHEMBL685145 0.92 1/20

Clinical trials — most relevant to BCL2L11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia PHASE2ACTIVE_NOT_RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL PHASE2RECRUITING
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission PHASE2ACTIVE_NOT_RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
SPC2996 in Chronic Lymphocytic Leukaemia PHASE1/PHASE2COMPLETED
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML PHASE2ACTIVE_NOT_RECRUITING
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. PHASE2ACTIVE_NOT_RECRUITING
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma PHASE1/PHASE2NOT_YET_RECRUITING
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
Safe Accelerated Venetoclax Escalation in CLL PHASE1ACTIVE_NOT_RECRUITING
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases PHASE1COMPLETED
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma PHASE1ACTIVE_NOT_RECRUITING
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan nanUNKNOWN
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings nanACTIVE_NOT_RECRUITING
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease nanTEMPORARILY_NOT_AVAILABLE
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BCL2L11 binder may also engage these)

ProteinNameSimilarity
O54918 — 1.000 O54918 →
O88498 — 0.997 O88498 →
Q6P1L5 — 0.975 Q6P1L5 →
Q86VQ1 — 0.974 Q86VQ1 →
Q8K3I9 — 0.970 Q8K3I9 →
Q3U3E2 — 0.970 Q3U3E2 →
Q80U23 — 0.968 Q80U23 →
A0A088MLT8 — 0.968 A0A088MLT8 →
Q80U62 — 0.968 Q80U62 →
Q3USH1 — 0.968 Q3USH1 →
Q6ZNC4 — 0.968 Q6ZNC4 →
Q7TNF9 — 0.968 Q7TNF9 →
P12755 — 0.967 P12755 →
O15079 — 0.967 O15079 →
Q9C073 — 0.967 Q9C073 →
Q62925 — 0.967 Q62925 →
G3V9M2 — 0.967 G3V9M2 →
Q8BGW2 — 0.967 Q8BGW2 →
P0DPB3 — 0.966 P0DPB3 →
P78524 — 0.966 P78524 →
B3KU38 — 0.966 B3KU38 →
Q9WVI9 — 0.965 Q9WVI9 →
Q9TUG2 — 0.965 Q9TUG2 →
Q6UXB0 — 0.965 Q6UXB0 →
Q8BXL9 — 0.965 Q8BXL9 →
A6P320 — 0.965 A6P320 →
Q68FF7 — 0.965 Q68FF7 →
Q8K589 — 0.965 Q8K589 →
Q8BWU3 — 0.965 Q8BWU3 →
A2A9T0 — 0.964 A2A9T0 →